Valuation: CSL Limited

Market Cap 59.78B 52.13B 49.22B 44.7B 83.74B 5,736B 84.09B 590B 228B 2,916B 225B 220B 9,384B P/E 2027 *
20.6x
P/E 2028 * 18.6x
Enterprise Value 68.96B 60.13B 56.78B 51.56B 96.6B 6,617B 97B 680B 262B 3,364B 259B 253B 10,824B EV / Sales 2027 *
4.37x
EV / Sales 2028 * 4.21x
Free-Float
99.97%
Yield 2027 *
2.4%
Yield 2028 * 2.55%
1 day-1.11%
1 week+5.08%
Current month+2.34%
1 month+11.26%
3 months+62.46%
6 months+27.24%
Current year+1.70%
1 week 166.43
Extreme 166.43
177.97
1 month 165.79
Extreme 165.79
177.97
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+5.08%-11.47%-33.91% 60.48B
-0.58%+0.43%+31.09%-4.81% 78.83B
-2.55%+6.99%+505.27%+47.92% 63.11B
+0.14%-1.20%-11.64%+24.21% 46.75B
-0.24%+1.22%+2.26%+151.03% 45.66B
-1.62%-0.76%+49.85%-14.92% 32.37B
-1.81%+3.16%+45.71%+110.57% 25.87B
+0.47%+3.26%-0.77%+142.41% 21.33B
+0.27%+1.96%+62.19%+102.81% 15.8B
-1.04%-8.05%+24.90%+133.39% 13.16B
Average -0.81%+1.06%+69.74%+65.87% 40.33B
Weighted average by Cap. -0.93%+1.92%+92.46%+43.18%

Financials

2027 *2028 *
Net sales 15.77B 13.75B 12.98B 11.79B 22.09B 1,513B 22.18B 155B 60B 769B 59.22B 57.91B 2,475B 16.31B 14.22B 13.43B 12.2B 22.85B 1,565B 22.95B 161B 62.08B 796B 61.27B 59.91B 2,560B
Net income 2.82B 2.46B 2.32B 2.11B 3.96B 271B 3.97B 27.85B 10.75B 138B 10.61B 10.37B 443B 3.16B 2.75B 2.6B 2.36B 4.43B 303B 4.44B 31.16B 12.02B 154B 11.87B 11.6B 496B
Net Debt 9.18B 8B 7.56B 6.86B 12.86B 881B 12.91B 90.51B 34.93B 448B 34.47B 33.71B 1,440B 8.86B 7.72B 7.29B 6.62B 12.41B 850B 12.46B 87.34B 33.7B 432B 33.27B 32.53B 1,390B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-18 A$175.59 -1.11% 4,246,940
26-09-17 A$177.56 +1.81% 1,984,012
26-09-16 A$174.41 +0.09% 1,420,415
26-09-15 A$174.26 +1.57% 1,417,850
26-09-14 A$171.57 +2.68% 1,078,021
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
124.82USD
Average target price
126.29USD
Spread / Average Target
+1.17%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!